StockData
Ligand Pharmaceuticals Inc logo

Ligand Pharmaceuticals Inc (LGND) stock

LGNDNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as LGNDZ, LGNXZ, LGNYZ, LGNZZ
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 6/30433% above fair value
$293.81−7.90 (-2.62%)

Close on Nov 17, 2026Market cap $5.88BP/E 128.3Yield –

Ligand Pharmaceuticals total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Ligand Pharmaceuticals's total debt was $1.13B at Sep 30, 2026. For fiscal 2015 it was $205.37M, up 4.8% from the year before. The highest annual figure on record is $205.37M in fiscal 2015.

Annual total debt

PeriodPeriod endValueChange
FY2015Dec 31, 2015$205.37M+4.8%
FY2014Dec 31, 2014$195.91M–
FY2013Dec 31, 2013$0-100.0%
FY2012Dec 31, 2012$13.44M-33.7%
FY2011Dec 31, 2011$20.29M–
FY2010Dec 31, 2010$0–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$1.13B–

More Ligand Pharmaceuticals figures

See a number that looks wrong?